American College of Clinical Pharmacy
      Search      Cart
         

Navigating Regulatory and Payment Barriers to Medication Optimization: Advocating for Business Models that Sustain Clinical Practice

Saturday, October 26, 2019 from 9:45 AM to 11:45 AM EST at 2nd Floor: Nassau

Available for 2.00 hours of CPE credit
Activity Number: 0217-0000-19-156-L03-P
Activity Type: An Application-Based Activity


Speakers
  • John K. McGlew, M.A.Facilitator: John K. McGlew, M.A.
    Director, Government Affairs, American College of Clinical Pharmacy (ACCP), Washington, D.C.
      View Biography

  • Moderator: Kathy Pham, Pharm.D.

Getting the Definitions Right
9:45 AM to 10:15 AM

Speakers
  • Curtis E. Haas, Pharm.D., FCCP, BCPSSpeaker: Curtis E. Haas, Pharm.D., FCCP, BCPS
    Director of Pharmacy, University of Rochester Medical Center, Rochester, New York
      View Biography


Learning Objectives
Summarize the differences between collaborative practice agreements, standing orders, statewide protocols, and related terms.
Compare the application of these terms as mechanisms to expand clinical pharmacists’ scope of practice.
Identify key components of collaborative practice agreements that allow clinical pharmacists to effectively contribute to medication optimization
Making the Business Case: CMM in Value Based Payment and Delivery
10:15 AM to 10:45 AM

Speakers
  • Jon  Easter, B.S.Pharm.Speaker: Jon Easter, B.S.Pharm.
    Director, Center for Medication Optimization through Practice and Policy; Professor, Division of Practice Advancement and Clinical Education, University of North Carolina Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina
      View Biography


Learning Objectives
Describe the multimodal approach to advancing practice through policy change related to medication optimization across key payers and practice settings.
Describe how health policy decisions can incentivize new payment models and scale care delivery innovations that will improve patient outcomes and lower the total cost of care.
Discuss key concepts to supporting medication optimization in value-based care delivery and payment models
Summarize the importance of clinical practice and advocacy efforts to the advancement of clinical pharmacists’ contribution to achieving medication optimization.
Congressional and Legislative Advocacy
10:45 AM to 11:15 AM

Speakers
  • Paul T. KellySpeaker: Paul T. Kelly
    President, Capitol Advocacy and Government Affairs, LLC, Washington, D.C.


Learning Objectives
Describe the policy principles of ACCP’s Medicare Initiative to establish formal, statutory coverage for comprehensive medication management (CMM) services within the Medicare program beyond recognition as providers.
Describe why a comprehensive approach to policy change, including payment reform that formally integrates clinical pharmacists to achieve medication optimization, is essential in order to meaningfully address the needs of our health care system.
Describe how federal laws and regulations – including the Affordable Care Act (ACA) and the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) – can help support medication optimization in comprehensive medication management practices by advancing team-based patient-centered structures.
Identify key strategies for successful advocacy at the state and federal level that can enhance clinical pharmacists’ involvement in medication optimization beyond provider status recognition.
Panel Discussion
11:15 AM to 11:45 AM

Speakers
  • Speaker: Curtis E. Haas, Pharm.D., FCCP, BCPS
    Director of Pharmacy, University of Rochester Medical Center, Rochester, New York
      View Biography

  • Moderator: Kathy Pham, Pharm.D.

  • Speaker: Jon Easter, B.S.Pharm.
    Director, Center for Medication Optimization through Practice and Policy; Professor, Division of Practice Advancement and Clinical Education, University of North Carolina Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina
      View Biography

  • Speaker: Paul T. Kelly
    President, Capitol Advocacy and Government Affairs, LLC, Washington, D.C.